Quick Takeaways:
- Zpeer has launched A-DHA-PT, a high-concentration DHA supplement designed to support neurological health in dogs. Developed for conditions like idiopathic epilepsy, each 13 mm capsule delivers >150 mg DHA, with packs containing 120 capsules for efficient, low-burden administration
- The formulation is based on prior academic research and developed under the supervision of University of Tokyo’s Dr. Tomohiro Yonezawa. Manufactured in Japan using pharmaceutical-grade materials, the product aims to address rising interest in nutritional approaches for managing neurological disorders in companion animals
- Alongside the launch, Zpeer has entered a research collaboration with the University of Tokyo to further evaluate DHA’s clinical benefits in canine epilepsy. The studies will assess seizure outcomes and quality of life, aiming to strengthen evidence for DHA as part of nutritional management strategies in veterinary neurology
Why It Matters?
A-DHA-PT gives veterinary neurologists a standardized, high‑dose DHA option developed under academic supervision, potentially making nutritional add‑on therapy a more routine consideration in dogs with idiopathic epilepsy where pharmacologic control is incomplete.
By tying the launch to a formal University of Tokyo research collaboration on seizure outcomes and quality of life, Zpeer is positioning itself as an evidence‑driven neurology player and could help move omega‑3s from generic supplements toward protocolized, data‑backed use in veterinary epilepsy management.
Source: PRnewswire
